TOP HEADLINES

Featured Story

U.K. and CA companies to collaborate on breast cancer Dx study

The U.K.'s Abcodia will work with California-based OncoCyte to perfect a blood test for early breast cancer detection.

Amarantus scores a small victory in the advance of its Alzheimer's Dx test

Alzheimer's watchers are left for the moment focusing on small victories. Amarantus Bioscience Holdings recently accomplished one, completing enrollment in a planned study of 72 patients to assess the feasibility of LymPro, its Alzheimer's blood diagnostic test.

Belgium's VolitionRx touts positive early results for noninvasive colon cancer Dx

VolitionRx said it will pursue a CE mark application later in 2014 or early 2015, based, in part on initial positive results from a major study involving its noninvasive colorectal cancer diagnostic test panel.

Pittsburgh outfit launches blood Dx to measure pediatric transplant rejection risk

The FDA has signed-off on a new blood test that can help predict whether transplanted livers or intestines will be rejected after being implanted in children.

Gene-sequencing leukemia research could boost Dx and treatment for kids with a rare disease subtype

St. Jude Children's Research Hospital and colleagues from around the country used next-generation sequencing in a study that could upend how a high-risk leukemia subtype is diagnosed and treated in children and adolescents.

MORE NEWS

From Our Sister Sites

FiercePharma

Companies have been studying Stendra for some sort of competitive edge. Now, they may have found one: The FDA backed the ED pill as a fast-acting treatment, taken 15 minutes before sex. Previously, the directions prescribed a 30-minute lead time.

FiercePharma

With the Ebola death toll mounting in West Africa, a Phase I trial of GlaxoSmithKline's experimental vaccine for the disease is underway at the U.S. National Institutes of Health.